ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $51.09 and traded as high as $55.32. ProShares Ultra Nasdaq Biotechnology shares last traded at $55.26, with a volume of 6,354 shares.
ProShares Ultra Nasdaq Biotechnology Stock Performance
The firm's 50-day simple moving average is $51.50 and its 200 day simple moving average is $48.57. The stock has a market capitalization of $57.98 million, a P/E ratio of 20.68 and a beta of 1.63.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, July 1st. Stockholders of record on Wednesday, June 25th were issued a $0.1706 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, June 25th. This is a positive change from ProShares Ultra Nasdaq Biotechnology's previous quarterly dividend of $0.13.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Franklin Resources Inc. bought a new position in ProShares Ultra Nasdaq Biotechnology in the 2nd quarter valued at about $32,000. PNC Financial Services Group Inc. acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 1st quarter worth approximately $48,000. Laurel Wealth Advisors LLC boosted its position in ProShares Ultra Nasdaq Biotechnology by 4,481.0% in the second quarter. Laurel Wealth Advisors LLC now owns 13,743 shares of the exchange traded fund's stock valued at $630,000 after buying an additional 13,443 shares in the last quarter. Finally, IMC Chicago LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology in the first quarter valued at approximately $1,080,000.
ProShares Ultra Nasdaq Biotechnology Company Profile
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Recommended Stories
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
